id okr-10986-13730
recordtype oai_dc
spelling okr-10986-137302021-04-23T14:03:09Z An Analysis of Pharmaceutical Lending by the World Bank Rodríguez-Monguió, Rosa Rovira, Juan ANTIBIOTICS APPRAISAL REPORTS BORROWER COMPETITIVE BIDDING CONCESSIONAL LOANS CONTRACEPTIVES COST ACCOUNTING DEVELOPMENT GOALS DRUGS ECONOMICS EXPENDITURES FISCAL YEAR FOREIGN EXCHANGE HEALTH CARE HEALTH SECTOR HEALTH SERVICES HOSPITALS HUMAN CAPITAL INCOME LEGISLATION LENDING DOCUMENTS LENDING INSTRUMENTS LENDING OPERATIONS LOAN LOAN AGREEMENTS MEDICAL SUPPLIES MEDICINE NUTRITION PHARMACEUTICAL PRODUCTS PHARMACEUTICAL SECTOR PHARMACEUTICAL SUPPLIERS PHARMACEUTICALS PRIVATE SECTOR PROCUREMENT PROJECT IMPLEMENTATION PUBLIC HEALTH PUBLIC POLICIES PURCHASING RATIONAL USE OF DRUGS SANITATION SUPPLIERS TECHNICAL ASSISTANCE TRANSPARENCY TRUST FUNDS VACCINES VENEZUELA WATER SUPPLY LENDING LENDING OPERATIONS The World Bank (WB) began to lend for health, nutrition, and population (HNP) in the late 1970s. Today, the Bank has become the single largest external source of HNP financing in low- and middle-income countries. The Bank's activities in the HNP sector are based on the rationale that investments in health, nutrition, and population constitute an investment in human capital that is necessary for enhanced welfare, reduced poverty and sustainable growth. During fiscal years (FY) 1999 to 2002, the World Bank approved 683 lending projects in all sectors, with a total lending amount of US$ 38,306 million (2001 prices). During the same period of time, the World Bank approved 65 HNP lending projects, with a total cumulative value of US$ 3,298 million (2001 prices). The Bank has been financing pharmaceutical activities within the HNP portfolio since 1983. In total, the Bank has provided financing for pharmaceuticals in over 100 HNP projects in all six regions. According to the results of the present research, contracts for the procurement of pharmaceuticals and medical products (PMP) under Bank financed projects from FY 1999 to FY 2002 accounted for almost 36 percent of the procurement of goods in HNP, and for 18 percent of the total HNP procurement activity including goods, civil works, consulting and other services. Despite the increased interest in pharmaceuticals, lending in this area has been conducted without the guidance of an explicit operational policy on pharmaceuticals. While the World Bank has produced a number of policy papers and reports on pharmaceuticals, these are not considered operational policy. In this situation, good practices and implicit policy guide the pharmaceutical activities of the HNP sector and the Bank's pharmaceutical activities. 2013-05-30T20:57:16Z 2013-05-30T20:57:16Z 2004-09 http://documents.worldbank.org/curated/en/2004/09/5621115/analysis-pharmaceutical-lending-world-bank http://hdl.handle.net/10986/13730 English en_US Health, Nutrition and Population (HNP) discussion paper; CC BY 3.0 IGO http://creativecommons.org/licenses/by/3.0/igo/ World Bank World Bank, Washington, DC Publications & Research :: Working Paper Publications & Research
repository_type Digital Repository
institution_category Foreign Institution
institution Digital Repositories
building World Bank Open Knowledge Repository
collection World Bank
language English
en_US
topic ANTIBIOTICS
APPRAISAL REPORTS
BORROWER
COMPETITIVE BIDDING
CONCESSIONAL LOANS
CONTRACEPTIVES
COST ACCOUNTING
DEVELOPMENT GOALS
DRUGS
ECONOMICS
EXPENDITURES
FISCAL YEAR
FOREIGN EXCHANGE
HEALTH CARE
HEALTH SECTOR
HEALTH SERVICES
HOSPITALS
HUMAN CAPITAL
INCOME
LEGISLATION
LENDING DOCUMENTS
LENDING INSTRUMENTS
LENDING OPERATIONS
LOAN
LOAN AGREEMENTS
MEDICAL SUPPLIES
MEDICINE
NUTRITION
PHARMACEUTICAL PRODUCTS
PHARMACEUTICAL SECTOR
PHARMACEUTICAL SUPPLIERS
PHARMACEUTICALS
PRIVATE SECTOR
PROCUREMENT
PROJECT IMPLEMENTATION
PUBLIC HEALTH
PUBLIC POLICIES
PURCHASING
RATIONAL USE OF DRUGS
SANITATION
SUPPLIERS
TECHNICAL ASSISTANCE
TRANSPARENCY
TRUST FUNDS
VACCINES
VENEZUELA
WATER SUPPLY
LENDING
LENDING OPERATIONS
spellingShingle ANTIBIOTICS
APPRAISAL REPORTS
BORROWER
COMPETITIVE BIDDING
CONCESSIONAL LOANS
CONTRACEPTIVES
COST ACCOUNTING
DEVELOPMENT GOALS
DRUGS
ECONOMICS
EXPENDITURES
FISCAL YEAR
FOREIGN EXCHANGE
HEALTH CARE
HEALTH SECTOR
HEALTH SERVICES
HOSPITALS
HUMAN CAPITAL
INCOME
LEGISLATION
LENDING DOCUMENTS
LENDING INSTRUMENTS
LENDING OPERATIONS
LOAN
LOAN AGREEMENTS
MEDICAL SUPPLIES
MEDICINE
NUTRITION
PHARMACEUTICAL PRODUCTS
PHARMACEUTICAL SECTOR
PHARMACEUTICAL SUPPLIERS
PHARMACEUTICALS
PRIVATE SECTOR
PROCUREMENT
PROJECT IMPLEMENTATION
PUBLIC HEALTH
PUBLIC POLICIES
PURCHASING
RATIONAL USE OF DRUGS
SANITATION
SUPPLIERS
TECHNICAL ASSISTANCE
TRANSPARENCY
TRUST FUNDS
VACCINES
VENEZUELA
WATER SUPPLY
LENDING
LENDING OPERATIONS
Rodríguez-Monguió, Rosa
Rovira, Juan
An Analysis of Pharmaceutical Lending by the World Bank
relation Health, Nutrition and Population (HNP) discussion paper;
description The World Bank (WB) began to lend for health, nutrition, and population (HNP) in the late 1970s. Today, the Bank has become the single largest external source of HNP financing in low- and middle-income countries. The Bank's activities in the HNP sector are based on the rationale that investments in health, nutrition, and population constitute an investment in human capital that is necessary for enhanced welfare, reduced poverty and sustainable growth. During fiscal years (FY) 1999 to 2002, the World Bank approved 683 lending projects in all sectors, with a total lending amount of US$ 38,306 million (2001 prices). During the same period of time, the World Bank approved 65 HNP lending projects, with a total cumulative value of US$ 3,298 million (2001 prices). The Bank has been financing pharmaceutical activities within the HNP portfolio since 1983. In total, the Bank has provided financing for pharmaceuticals in over 100 HNP projects in all six regions. According to the results of the present research, contracts for the procurement of pharmaceuticals and medical products (PMP) under Bank financed projects from FY 1999 to FY 2002 accounted for almost 36 percent of the procurement of goods in HNP, and for 18 percent of the total HNP procurement activity including goods, civil works, consulting and other services. Despite the increased interest in pharmaceuticals, lending in this area has been conducted without the guidance of an explicit operational policy on pharmaceuticals. While the World Bank has produced a number of policy papers and reports on pharmaceuticals, these are not considered operational policy. In this situation, good practices and implicit policy guide the pharmaceutical activities of the HNP sector and the Bank's pharmaceutical activities.
format Publications & Research :: Working Paper
author Rodríguez-Monguió, Rosa
Rovira, Juan
author_facet Rodríguez-Monguió, Rosa
Rovira, Juan
author_sort Rodríguez-Monguió, Rosa
title An Analysis of Pharmaceutical Lending by the World Bank
title_short An Analysis of Pharmaceutical Lending by the World Bank
title_full An Analysis of Pharmaceutical Lending by the World Bank
title_fullStr An Analysis of Pharmaceutical Lending by the World Bank
title_full_unstemmed An Analysis of Pharmaceutical Lending by the World Bank
title_sort analysis of pharmaceutical lending by the world bank
publisher World Bank, Washington, DC
publishDate 2013
url http://documents.worldbank.org/curated/en/2004/09/5621115/analysis-pharmaceutical-lending-world-bank
http://hdl.handle.net/10986/13730
_version_ 1764424221379788800